Summary.-It has previously been shown that rat embryo cells treated in vitro with 3-methylcholanthrene (MCA) elicit antibodies in syngeneic rats which react specifically against established MCA-induced sarcomas. To examine the possibility that clonal amplification of one or a few antigenic, preneoplastic clones is responsible for the previously observed specific antibody responses, MCA-treated rat embryo cells have been subjected to 150 Gy of y-irradiation before injection into host animals. The resulting antisera were screened for reactivity against a panel of established syngeneic tumours by membrane immunofluorescence and an isotopic antiglobulin test. A positive reaction was observed between an antiserum pool raised against y -irradiated MCA -treated cells and the cells of an immunogenic spontaneous mammary carcinoma. Antiserum to y-irradiated control (acetone-treated) cells was negative. Thus yirradiation of carcinogen-treated cells before injection failed to abolish specific antibody responses in immunized rats. To investigate further the relationships between cell-carcinogen interaction, neoantigen induction and malignancy, the cells of a non-immunogenic, spontaneous mammary carcinoma were treated with MCA in vitro, and antisera against treated and untreated cells were tested against a panel of established tumours. A positive membrane-immunofluorescence reaction was obtained with an antiserum to MCA-treated cells, but not to untreated cells against an aminoazodye-induced hepatoma, indicating that the previously non-immunogenic mammary carcinoma cells had acquired new antigenic specificities as a consequence of carcinogen treatment.
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NEOPLASTIC TRANSFORMATION by chemical carcinogens often leads to the expression in the transformed cell of neoantigens which are not detectable on normal cells.
Classically, these antigens have been defined in tumours by experiments in which syngeneic hosts are pre-immunized with tumour prevented from progressive growth by surgical extirpation or attenuation, followed by challenge with viable tumour cells sufficient to cause progressive growth in controls. Antigens detected by a rejection response in such assays are termed tumour-associated rejection antigens (TARA) or tumour-associated transCorrespondence to: Dr M. J. Embleton. plantation antigens (TATA). Cell-surfaceassociated antigens are also detectable on many chemically induced tumours by serological assays involving sera from immune donors and in general these have the same distribution and selectivity as TARAs. In spite of this concordance of expression, it cannot with certainty be stated that serologically detected antigens are identical with TARAs, and they are therefore better designated separately as tumour-cell surface antigens (TCSA). However, since TARA and TCSA exist in parallel, the general features of their expression are common. Collectively, tumour neoantigens arise as a consequence of the interaction between cell and carcinogen (Embleton & Heidelberger, 1972 , 1975 and appear to be closely associated with tumorigenicity (Mondal et al., 1971) . However, despite this close association, their acquisition appears not to be an essential step in neoplastic transformation, since many chemically induced tumours and most spontaneous animal tumours have no neoantigens detectable by transplantation tests Baldwin & Embleton, 1969; Hewitt et al., 1976) . On the basis of these observations, the relationship between cell-carcinogen interaction, neoantigen induction and neoplastic transformation are unclear. It has recently been reported that rat embryo cells treated in vitro with 3-methylcholanthrene (MCA) acquire new cellsurface antigenic specificities which crossreact specifically and reproducibly with counterparts on certain established chemically induced tumours . These findings suggest that TCSAs of chemically induced tumours are not unique, but may be reproduced on carcinogen-treated cells or their progeny after only a short period of exposure to carcinogen. MCA-treated rat embryo cells failed to undergo neoplastic transformation during the course of these studies, as evidenced by the absence of macroscopic tumours in immunized animals, and extranuclear membrane preparations of MCAtreated cells did not induce antibody responses, indicating that new surface antigens were probably not produced during the short exposure to carcinogen. Thus it seems most likely that neoantigen specificities are acquired during some stage of preneoplastic development occurring after injection of MCA-treated cells into the host. In the present study we have investigated the possibility that clonal amplification of one, or a few, antigenic clones after injection of MCA-treated cells into the host animal is responsible for the observed specific antibody responses. Carcinogen-treated rat embryo cells were therefore subjected to y-irradiation before immunization and the resulting antisera were screened against a panel of established rat tumours.
In order to investigate further the relationship between cell-carcinogen interaction, neoantigen expression and malignant transformation we have also treated the cells of non-immunogenic spontaneous mammary carcinoma in vitro with MCA, and have looked for specific antibody responses in syngeneic rats immunized with these cells, to determine whether carcinogen treatment would induce neoantigen expression in cells whichare already neoplastic.
MATERIALS AND METHODS
Rats.-Inbred WAB/Not rats were used both for immunological studies and as donors of embryos and syngeneic tumours.
Carcinogen treatment.-Single-cell suspensions were prepared from minced 17-19-day rat embryos and from mammary carcinoma Sp15 by repeated treatment with 0 25% trypsin (Difco). Mammary carcinoma Spi5 was of spontaneous origin and is nonimmunogenic in syngeneic rats. Between 5 x 107 and 10 viable embryo or tumour cells were plated in 100mm non-tissue-culture Petri dishes (Oxoid) in 10 ml Eagle's MEM supplemented with calf serum (10%), penicillin (200 i.u./ml), streptomycin (100 ,ug/ml) and either 0-500 acetone or 0-500 acetone containing 2 mg/ml 3-methylcholanthrene (MCA, Sigma). The final concentration of MCA in the medium was 10 ,ug/ml. Dishes were incubated for 18 h at 37°C in an atmosphere of 5% CO2 in air and the cells harvested by aspiration and rinsing. Cells were subsequently washed x 6 in Hanks' balanced salt solution (HBSS) and recounted.
y-irradiation and immunization.-Before injection into host animals, rat embryo and Spl5 tumour cells were exposed to 150 Gy y-irradiation from a cobalt-60 source. The cells were then injected i.p. into syngeneic male rats, each rat receiving the cellular contents of one dish (2-5 x 107 viable cells). Four injections were given at 10-day intervals and the rats bled by cardiac puncture 7 days after the 4th injection. Serum was prepared from clotted blood, and samples from rats receiving identical treatments were pooled and stored at -20°C in small aliquots.
In another experimental design, mammary carcinoma Spl5 cells were treated in vitro with either MCA or acetone as previously described, cells were washed x 6 and 1 ml of a suspension containing either 106 viable MCA-or acetone-treated Spl5 cells was injected i.p. into syngeneic animals; all rats developed tumours within 3 weeks. A singlecell suspension of each tumour was then prepared by trypsinization, and 1 ml containing 106 cells of this was injected i.p. into syngeneic rats. Each tumour cell line was subsequently maintained in vitro by successive i.p. transplantation of 106 tumour cells. In this way 6 tumour lines were prepared, 3 derived from Spl5 cells treated in vitro with MCA and 3 from Spl5 cells treated in vitro with acetone.
To investigate whether tumour lines derived from Spl5 cells treated in vitro with MCA had acquired immunogenic potential (new antigenic specificities), an antiserum was raised against each tumour line in the following way: at each in vivo passage, after removal of 106 cells for line maintenance, the remainder of the tumour single cell suspension was exposed to 150 Gy of y-irradiation and 1-5 x 107 cells were injected i.p. into each of 7 syngeneic rats. This procedure was repeated x 4, animals being bled by cardiac puncture 7 days after administration of the final inoculum. Serum was prepared and stored as previously described.
Membrane immunofuorescence test.-Sera were tested for reactivity against a range of WAB/Not rat tumours using a membrane immunofluorescence test performed on viable suspended cells (Baldwin et al., 1971 (Baldwin et al., 1971 ).
The specificity of any positive reactions was examined by a series of absorption tests. Aliquots of serum were absorbed for 2 h at 4°C with tumour cells at a density of 108 cells/ml of serum. Cells were removed by centrifugation and the absorbed sera were tested for reactivity against selected target cells. A reduction of more than 50% in Fl with absorbed serum compared with that obtained with unabsorbed serum was taken to represent a significant degree of antibody absorption.
Isotopic antiglobulin te8t.-Sera were also tested for reactivity against certain tumour target cells, using an isotopic antiglobulin test (Williams et al., 1977) . Dilutions of each antiserum were prepared in HBSS containing 1% bovine serum albumin (BSA, Sigma). 100 ,ul aliquots of diluted antiserum were incubated in triplicate with 105 tumour target cells for 1 h on ice. Cells were washed x 3 in HBSS containing 0.1% BSA and incubated for 1 h on ice with 50 1l of 1% BSA containing 1251-labelled sheep F(ab)2 anti-rat IgG. Each cell suspension received 7 ng protein, to give between 2 x 105 and 3 x 105 ct/min. Cells were washed x 6 in HBSS containing 01% BSA, centrifuged and the cell pellets counted in a gamma counter.
The mean ct/min obtained with antisera raised to MCA-treated cells were compared with the mean ct/min with antisera to acetonetreated cells, and with normal rat serum. Data were analysed by a single-classification analvsis of variance.
Metabolism of 3H-MCA by Spl5 mammary carcinoma cells.-The ability of mammary carcinoma Spl5 cells to take up and metabolize MCA was determined as described by Diamond et al. (1968) . Mammary carcinoma SpI5 cells (5 x 107) were plated into 100mm Oxoid dishes in 10 ml medium containing 10 jug/ml MCA, of which 5 ng/ml was 3H-MCA (0 5 ,uCi/ml). Cells were incubated at 37°C for 18 h, centrifuged and the supernatant collected. The cell pellet was washed x 3, solubilized in 3M KOH and diluted in 5 vols of methanol before assaying for radioactivity. The supernatant was extracted in a mixture of 20 vols of chloroform: methanol (2:1 v/v) and 4 vols of water. The aqueous and organic solvent fractions of the extraction mixture were separated and assayed for activity in a / counter.
After t Serum was absorbed for 2 h at 4°C using 108 cells/ml of serum, which were removed by centrifugation at 10,000 g for 10 min. The positive membrane-immunofluorescence reaction between A5104 and Sp4 and the specificity of this reaction have been confirmed using the isotopic antiglobulin test. Thus in 3 independent tests the mean ct/min when A5104 was reacted with Sp4 target cells was significantly higher than that obtained with either the acetone control antiserum (A5105) or normal rat serum (Table IV) Data were analysed by single-classification analysis of variance: the mean ct/min with A5104 was significantly higher than that obtained with either A5105 or normal rat serum (P < 0-01). t See Table I (Table IV) . This antiserum, A5764, was consistently positive in each of 3 independent tests, and the specificity of the reactions was confirmed by a series of absorption tests (Table VII) The positive reaction between antiserum A5764 and Sp4 was also confirmed by the isotopic antiglobulin test. In 2 independent tests the mean ct/min when A5764 was reacted against Sp4 target cells was significantly higher than that obtained (Lappe, 1969) .
The results obtained when the cells of mammary carcinoma Spl5 were incubated in the presence of 3H-MCA indicate that these cells are able to bind and metabolize MCA under the culture conditions previously described. Also an antiserum raised to MCA-treated SpI5 cells reacted consistently and reproducibly with the cells of an aminoazodye-induced hepatoma, D192A. One interpretation of these findings is that as a result of carcinogen treatment these previously non-immunogenic cells have acquired neoantigen specificities which are absent from untreated cells, and if so, that, as previously suggested by , chemically induced neoantigens are not specific for a particular carcinogen. Furthermore, these results indicate that neoantigen specificities can be induced on already neoplastic cells.
In the second experimental design, an antiserum raised against a tumour derived from Sp15 cells treated in vitro with MCA reacted consistently and reproducibly with the cells of the spontaneous immunogenic mammary carcinoma, Sp4. The corresponding tumour derived from acetone-treated Spl5 cells failed to elicit Sp4 antiserum reactivity, suggesting that the observed reactivity of antiserum A5764 with Sp4 cells arose through the in vitro treatment of SpI5 cells with MCA. One interpretation of this finding is that the carcinogen-treated Sp15 tumour cells have acquired an antigenic specificity which is the same as, or similar to, the TCSA of Sp4.
Since the experimental design used in this study makes it possible to reclaim carcinogen-treated cells as overt tumour, following injection into host animals, we should now be able to test directly whether or not cells treated in vitro with carcinogen do indeed express TCSA, and perhaps whether TCSA and TARA are identical. Previous studies have shown that carcinogen-treated rat embryo cells, while capable of expressing neoantigens which cross-react with their counterparts on certain established tumours, failed to manifest malignancy during the course of these studies . This observation, together with the apparent induction of neoantigens on already neoplastic cells, may indicate that the induction of new antigenic specificities by MCA is not necessarily related to the change from the normal to the neoplastic phenotype.
